(Q33962049)

30 July 2017

1 reference

title

Current status of antiangiogenic factors (English)

1 reference

30 July 2017

angiogenesis inhibitor

1 reference

K L Talks

1

1 reference

PubMed ID

10886192

30 July 2017

A L Harris

series ordinal

2

1 reference

PubMed ID

10886192

30 July 2017

language of work or name

English

0 references

publication date

1 June 2000

1 reference

British Journal of Haematology

30 July 2017

1 reference

30 July 2017

109

1 reference

30 July 2017

477-489

1 reference

30 July 2017

3

1 reference

Comparative expression of fibroblast growth factor mRNAs in benign and malignant breast disease

30 July 2017

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2141.2000.01864.X

Cancer treatment by targeted drug delivery to tumor vasculature in a mouse model

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2141.2000.01864.X

Oncogenic H-ras stimulates tumor angiogenesis by two distinct pathways

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2141.2000.01864.X

Release of the angiogenic cytokine vascular endothelial growth factor (VEGF) from platelets: significance for VEGF measurements and cancer biology.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2141.2000.01864.X

Selective ablation of immature blood vessels in established human tumors follows vascular endothelial growth factor withdrawal

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2141.2000.01864.X

Effects of angiogenesis inhibitors on multistage carcinogenesis in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2141.2000.01864.X

Antiangiogenic therapy of experimental cancer does not induce acquired drug resistance.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2141.2000.01864.X

The role of hepatocyte growth factor and its receptor c-Met in multiple myeloma and other blood malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2141.2000.01864.X

The anti-proliferative effect of suramin towards tamoxifen-sensitive and resistant human breast cancer cell lines in relation to expression of receptors for epidermal growth factor and insulin-like growth factor-I: growth stimulation in the presence

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2141.2000.01864.X

A structure-activity analysis of antagonism of the growth factor and angiogenic activity of basic fibroblast growth factor by suramin and related polyanions

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2141.2000.01864.X

Integrin alpha v beta 3 antagonists promote tumor regression by inducing apoptosis of angiogenic blood vessels

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2141.2000.01864.X

Disruption of angiogenesis by PEX, a noncatalytic metalloproteinase fragment with integrin binding activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2141.2000.01864.X

Role of HIF-1alpha in hypoxia-mediated apoptosis, cell proliferation and tumour angiogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2141.2000.01864.X

Role of tissue factor in embryonic blood vessel development.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2141.2000.01864.X

Farnesyltransferase inhibitors and cancer treatment: targeting simply Ras?

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2141.2000.01864.X

Thalidomide is an inhibitor of angiogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2141.2000.01864.X

Blood vessel maturation: vascular development comes of age

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2141.2000.01864.X

Isolation of angiopoietin-1, a ligand for the TIE2 receptor, by secretion-trap expression cloning

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2141.2000.01864.X

Elevated levels of the angiogenic cytokines basic fibroblast growth factor and vascular endothelial growth factor in sera of cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2141.2000.01864.X

The biology of vascular endothelial growth factor

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2141.2000.01864.X

What Is the Evidence That Tumors Are Angiogenesis Dependent?

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2141.2000.01864.X

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2141.2000.01864.X

The endogenous oestrogen metabolite 2-methoxyoestradiol inhibits angiogenesis and suppresses tumour growth

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2141.2000.01864.X

Markers of tumor angiogenesis: clinical applications in prognosis and anti-angiogenic therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2141.2000.01864.X

Tumor necrosis factor type alpha, a potent inhibitor of endothelial cell growth in vitro, is angiogenic in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2141.2000.01864.X

Tumor Growth and Neovascularization: An Experimental Model Using the Rabbit Cornea 2

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2141.2000.01864.X

Paracrine expression of a native soluble vascular endothelial growth factor receptor inhibits tumor growth, metastasis, and mortality rate

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2141.2000.01864.X

A tumor suppressor-dependent inhibitor of angiogenesis is immunologically and functionally indistinguishable from a fragment of thrombospondin

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2141.2000.01864.X

The hypoxic response: huffing and HIFing

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2141.2000.01864.X

Pericytes in the microvasculature

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2141.2000.01864.X

Tumor hypoxia in pelvic recurrences of cervical cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2141.2000.01864.X

Synthetic analogues of fumagillin that inhibit angiogenesis and suppress tumour growth

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2141.2000.01864.X

Antiangiogenic therapy of a recurrent giant cell tumor of the mandible with interferon alfa-2a.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2141.2000.01864.X

Effects of thalidomide and related metabolites in a mouse corneal model of neovascularization

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2141.2000.01864.X

Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2141.2000.01864.X

Gene therapy strategies for tumor antiangiogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2141.2000.01864.X

Antiangiogenic gene therapy targeting the endothelium-specific receptor tyrosine kinase Tie2

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2141.2000.01864.X

Inhibition of Angiogenesis by Recombinant Human Platelet Factor-4 and Related Peptides

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2141.2000.01864.X

Angiopoietin-2, a natural antagonist for Tie2 that disrupts in vivo angiogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2141.2000.01864.X

Combined effects of angiostatin and ionizing radiation in antitumour therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2141.2000.01864.X

Hypoxia-inducible factor-1 modulates gene expression in solid tumors and influences both angiogenesis and tumor growth.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2141.2000.01864.X

The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2141.2000.01864.X

The widespread expression of angiogenin in different human cells suggests a biological function not only related to angiogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2141.2000.01864.X

Thymidine phosphorylase is angiogenic and promotes tumor growth.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2141.2000.01864.X

Identification of a fibroblast-derived epithelial morphogen as hepatocyte growth factor

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2141.2000.01864.X

Interferon alfa-2a therapy for airway hemangiomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2141.2000.01864.X

Endostatin: an endogenous inhibitor of angiogenesis and tumor growth

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2141.2000.01864.X

Angiostatin: a novel angiogenesis inhibitor that mediates the suppression of metastases by a Lewis lung carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2141.2000.01864.X

Vasostatin, a calreticulin fragment, inhibits angiogenesis and suppresses tumor growth

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2141.2000.01864.X

Do mast cells help to induce angiogenesis in B-cell non-Hodgkin's lymphomas?

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2141.2000.01864.X

Bone marrow angiogenesis and mast cell density increase simultaneously with progression of human multiple myeloma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2141.2000.01864.X

Mechanisms of angiogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2141.2000.01864.X

Transforming growth factor type beta: rapid induction of fibrosis and angiogenesis in vivo and stimulation of collagen formation in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2141.2000.01864.X

HIF-1 alpha is required for solid tumor formation and embryonic vascularization.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2141.2000.01864.X

Hypoxia-inducible factor 1alpha (HIF-1alpha) protein is rapidly degraded by the ubiquitin-proteasome system under normoxic conditions. Its stabilization by hypoxia depends on redox-induced changes

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2141.2000.01864.X

Platelet number and interleukin-6 correlate with VEGF but not with bFGF serum levels of advanced cancer patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2141.2000.01864.X

The aminosterol antibiotic squalamine permeabilizes large unilamellar phospholipid vesicles.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2141.2000.01864.X

A nuclear factor induced by hypoxia via de novo protein synthesis binds to the human erythropoietin gene enhancer at a site required for transcriptional activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2141.2000.01864.X

Failure of blood-island formation and vasculogenesis in Flk-1-deficient mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2141.2000.01864.X

Leflunomide and malononitrilamides

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2141.2000.01864.X

The anti-angiogenic agent fumagillin covalently binds and inhibits the methionine aminopeptidase, MetAP-2

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2141.2000.01864.X

Interferons alpha and beta down-regulate the expression of basic fibroblast growth factor in human carcinomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2141.2000.01864.X

Paclitaxel. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential in the treatment of cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2141.2000.01864.X

Requisite role of angiopoietin-1, a ligand for the TIE2 receptor, during embryonic angiogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2141.2000.01864.X

Endothelial PAS domain protein 1 (EPAS1), a transcription factor selectively expressed in endothelial cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2141.2000.01864.X

Human lymphoblastoid cells produce extracellular matrix-degrading enzymes and induce endothelial cell proliferation, migration, morphogenesis, and angiogenesis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2141.2000.01864.X

Angiogenesis in B cell lymphoproliferative diseases. Biological and clinical studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2141.2000.01864.X

Angiogenesis extent and macrophage density increase simultaneously with pathological progression in B-cell non-Hodgkin's lymphomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2141.2000.01864.X

Bone marrow angiogenesis and progression in multiple myeloma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2141.2000.01864.X

Inhibition of angiogenesis in vivo by interleukin 12.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2141.2000.01864.X

Soluble E-selectin in cancer patients as a marker of the therapeutic efficacy of CM101, a tumor-inhibiting anti-neovascularization agent, evaluated in phase I clinical trail

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2141.2000.01864.X

Tumor angiogenesis and metastasis--correlation in invasive breast carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2141.2000.01864.X

Angiogenesis and tumor metastasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2141.2000.01864.X

Anti-angiogenic therapies in cancer clinical trials.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2141.2000.01864.X

Nitric oxide synthase lies downstream from vascular endothelial growth factor-induced but not basic fibroblast growth factor-induced angiogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2141.2000.01864.X

Antitumor Activity of Combined Blockade of Epidermal Growth Factor Receptor and Protein Kinase A

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2141.2000.01864.X

Targeting gene expression to hypoxic tumor cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2141.2000.01864.X

Angiogenesis, assessed by platelet/endothelial cell adhesion molecule antibodies, as indicator of node metastases and survival in breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2141.2000.01864.X

Interleukin-4 is a potent mitogen for capillary endothelium

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2141.2000.01864.X

10.1046/J.1365-2141.2000.01864.X

21 January 2018

Identifiers

DOI

1 reference

30 July 2017

1 reference

PubMed ID

10886192